PDF Summary:Sickening, by John Abramson

In the medical field, patients trust that pharmaceuticals and treatments are backed by rigorous, impartial research. But as John Abramson reveals in Sickening, pharmaceutical companies often exploit gaps in oversight, selectively using or withholding data to cast their products in a favorable light—regardless of actual risks and efficacy.

Through sobering case studies like Vioxx and Neurontin, Abramson exposes tactics used by drug manufacturers to manipulate research, promote unapproved uses, and obscure negative findings. He makes a compelling case that without systemic changes to clinical trial practices and tighter regulation, profit motives will continue to undermine the integrity of medical knowledge and place patients at risk.

(continued)...

• Engage in a peer-to-peer support group to share experiences and gather anecdotal evidence about what works for others with neuropathic pain. While this isn't scientific data, personal stories can provide insights into pain management strategies that you might not have considered.
• Educate yourself on the regulations surrounding medications by visiting government websites like the FDA to understand what off-label promotion means and why it's regulated. This knowledge will help you make informed decisions when discussing medications with healthcare providers and will empower you to report any suspicious activity you might encounter.

Pfizer Violated RICO Laws but Faced Only Modest, Undeterrent Penalties

In 2010, a jury found Pfizer guilty of fraudulent marketing and racketeering in connection with Neurontin, but the company faced a penalty totaling $142 million—a fraction of the billions earned from Neurontin sales. No individuals were penalized, which permitted pharmaceutical companies to function under a framework where they benefited more from breaking the law and paying fines than from following ethical and legal guidelines.

Practical Tips

• Create a personal policy for ethical investing by screening potential investments for corporate behavior. If you're interested in investing, even at a small scale, use tools like ESG (Environmental, Social, Governance) ratings to assess whether a company's profits are aligned with ethical practices. This way, you can ensure your investments contribute to responsible business conduct.
• Implement a 'violation jar' in your household or workplace, similar to a swear jar, where you contribute a set amount of money for every rule or agreement you break. Decide on a collective goal for the funds, such as a group outing or a donation to a cause everyone cares about. This tangible consequence for violations not only deters unwanted behavior but also turns mistakes into positive outcomes.
• Advocate for stronger enforcement and penalties for unethical business practices within your community or professional network. Start discussions on social media or write to your local representatives to express your concern about the lack of deterrence for unethical behavior in businesses. By raising awareness and pushing for change, you contribute to creating an environment where ethical practices are the norm and penalties are significant enough to deter misconduct.
• Engage in shareholder advocacy if you own stocks in pharmaceutical companies. Use your position as a shareholder to attend meetings, vote on proposals, and support initiatives that encourage ethical behavior and compliance with laws. Even small shareholders can join forces to submit shareholder resolutions or support existing ones that aim to hold companies accountable for their actions.

Impact of Commercialization on Integrity in Medical Research

This section explores the author's thesis: that the changing landscape of American society and the prioritization of corporate profits has led to a decline in the integrity and transparency of medical studies, rendering patient care vulnerable to commercial interests.

Drug Companies Influence Clinical Research, Design, Data Analysis, and Publication

This section outlines Abramson's argument that the shift in funding and management of research on treatments from independent universities to commercially driven entities has resulted in a system where the research information provided to physicians is often biased toward maximizing sales rather than optimizing treatments.

Public Funding for Medical Research Declines; Industry Sponsorship Shapes Agenda

Abramson points to a crucial shift starting in the latter part of the 1970s and picking up speed in the 1980s. As government support for medical studies decreased, pharmaceutical companies stepped in to cover the shortfall. Encouraged by legislation like the Bayh-Dole Act, which allowed for the commercialization of federally funded research, academic medical centers increasingly relied on industry funding, leading to a blurring of boundaries between independent scientific inquiry and commercial interests.

Practical Tips

• Create a personal donation plan to support medical research by identifying organizations that fund medical studies. Research non-profit organizations and foundations that provide financial support for medical research. Determine how much you can afford to donate regularly, even if it's a small amount. Set up a monthly donation to one or more of these organizations, thus contributing directly to the advancement of medical studies in the absence of government funding.
• Start a blog or social media page where you review and discuss the impact of pharmaceutical funding on medical research. This creates a platform for public awareness and discussion. You could write about different medications, the companies behind them, and how their research funding affects the end product. Engage your audience by asking for their opinions and experiences, fostering a community that values informed choices.
• Attend industry conferences with a focus on innovation to network with researchers and entrepreneurs. These events are where the latest federally funded research projects are often discussed. Networking here can provide insights into which projects have commercial potential and may lead to collaborative opportunities.
• Start a discussion with your healthcare provider about the influence of industry funding on the treatments they recommend. During your next appointment, ask questions like "How do you stay informed about the latest treatments?" or "What influences your decision when recommending a medication?" This can provide insight into how industry funding might affect medical practice and help you make more informed decisions about your care.
• You can scrutinize the funding sources of scientific research before trusting its findings by checking the acknowledgments or disclosures section of research papers. If a study is funded by a company that could benefit from certain results, approach the findings with a healthy dose of skepticism. For example, if a new study claims that a specific type of snack is surprisingly healthy, but it's funded by a snack company, consider the potential for bias before changing your diet.

Pharmaceutical Companies Use Contracts to Manage Trial Results and Publications

By the mid-1990s, commercial influence had become entrenched, with drug companies designing studies, analyzing data, and shaping publications to benefit their products. They shifted from primarily using university-affiliated hospitals to conduct trials to hiring contract research organizations (CROs), thus increasing their influence and reducing academic oversight. Tellingly, Abramson cites a 2004 survey revealing that 80% of research contracts between academic institutions and industries allowed the funding bodies to own the data, and 50% granted the funding bodies the right to write publication drafts, relegating academic authors to a passive role.

Other Perspectives

• University-affiliated hospitals may have competing priorities, such as education and patient care, that could potentially slow down the pace of clinical trials compared to CROs focused solely on research.
• CROs are subject to regulatory oversight and must adhere to Good Clinical Practice (GCP) guidelines, which are designed to ensure the integrity of trial results regardless of who conducts the research.
• Data ownership by industries could restrict the sharing of information, which could impede progress in the field by not allowing other researchers to build upon the findings.
• The percentage of contracts that allow funding bodies to draft publications does not reflect the quality or accuracy of the research presented in those publications.

Without Unbiased Data, Those Who Review and Edit Can Not Verify Study Validity and Exhaustiveness

This lack of data transparency, argues Abramson, creates a fundamental flaw in peer review. With drug companies controlling the data and often ghostwriting journal articles, those responsible for reviewing and editing peers' work can't independently check if the study results are correct and comprehensive, since they lack access to raw data. This leaves doctors with an illusion of evidence-based medicine, unaware of the commercial bias embedded in their trusted sources of information.

Context

• This practice involves hiring professional writers to produce articles that are then attributed to academic researchers. It can obscure the true authorship and introduce bias, as the ghostwriters may emphasize favorable results.
• The inability to reproduce study results is a significant issue in science. Access to raw data is crucial for replication efforts, which help confirm the reliability of scientific findings.
• Clinical guidelines, which inform medical practice, are often based on published research. If this research is biased, it can lead to guidelines that do not accurately reflect the best available evidence.

Industry Influence Compromises Reliability of Systematic Assessments and Meta-Analyses

This section focuses on how commercial influence extends beyond individual studies to meta-analyses and systematic reviews, further distorting the scientific evidence base relied upon by doctors.

Industry-Funded Meta-Analyses Report More Favorable Results For Sponsors

Abramson examines a worrisome trend: The majority of analyses that combine data from multiple trials are also funded or authored by individuals with industry ties, leading to biased conclusions. He cites studies showing that industry-funded meta-analyses are more likely to wholeheartedly recommend the medication from the sponsor, further compromising this critical source of reliable information for doctors.

Context

• Industry funding can shape the research agenda, focusing on profitable areas rather than those most beneficial to public health.
• Studies with positive results are more likely to be published, especially when funded by industry. This can skew the data available for meta-analyses, leading to overly favorable conclusions about a product's efficacy.
• There is ongoing debate about the need for stricter regulations and transparency in disclosing conflicts of interest in research to ensure that meta-analyses remain objective and reliable.

Cochrane Collaboration's Attempts to Obtain Complete Clinical Data Are Hindered, Undermining Review Integrity

Even the Cochrane organization, a highly respected independent entity dedicated to producing impartial reviews of the evidence, faces challenges in accessing complete data, as illustrated by the Tamiflu case. Roche, the manufacturer, initially refused to provide complete clinical trial reports, leading to a Cochrane review based on incomplete data, overstating the drug's benefits. It took years of effort by the reviewers and the BMJ for Roche to finally release all its Tamiflu trial data, revealing minimal clinical benefit and potential harms.

Practical Tips

• Develop a habit of seeking second opinions on medication by consulting with a different healthcare professional or using reputable online medical resources. This can provide a broader perspective and help you assess the validity of the drug's purported benefits.
• You can foster transparency in healthcare by requesting full disclosure of clinical trial data when considering medications. When you have a prescription filled, ask your pharmacist or doctor if the drug's clinical trial data is publicly available. This encourages healthcare professionals to consider the importance of transparency and may lead them to advocate for it within their networks.

Corporate Effects on Clinical Guidelines and Medical Knowledge

This section addresses Abramson's concern about the commercial bias embedded in the guidelines for clinical practice and insufficient oversight of drug efficacy and pricing in the U.S., resulting in a system geared toward maximizing industry profits at the expense of patient health and well-being.

Industry Funding and Conflicts Influence Professional Societies and Protocol Committees

Abramson highlights the pervasive influence of industry funding on practice guidelines, which are crucial to doctors for evidence-based recommendations. He points out major financial connections between guideline authors and pharmaceutical firms, leading to recommendations that often favor costly, newly developed drugs over effective, cheaper options.

Guidelines Favor Costly New Drugs Over Effective, Cheaper Alternatives Despite Lacking Evidence

Abramson provides several examples of how commercially influenced guidelines result in the promotion of costly medications with limited benefits. He cites the cholesterol guidelines from 2001 and 2004, which recommend statins for healthy women despite the lack of supporting clinical trials, the recommendation of expensive insulin analogs over far cheaper and equally effective human insulin for type 2 diabetes, and the overuse of biologics like Humira for rheumatoid arthritis when conventional drugs are less costly and just as effective.

Practical Tips

• Develop a habit of asking for generic alternatives whenever you receive a new prescription. Generics often offer the same benefits as brand-name drugs but at a lower cost. Make a note of the savings and any differences in how you feel or the results you achieve.
• Organize a peer-led book club focused on health literacy, where members read and discuss various health topics, including cholesterol management. This encourages learning from each other's experiences and insights. For instance, one session could be dedicated to discussing the role of statins and lifestyle changes in managing cholesterol, without any medical jargon, making the information accessible to all members.
• Create a medication expense diary to track the costs and effects of your current insulin regimen. Note down any side effects, blood sugar levels, and overall well-being to assess if a switch to a more cost-effective insulin could be justified.

Attempts to Enhance Transparency and Manage Conflicts in Guidelines Fail

Efforts to address this conflict of interest, such as the Institute of Medicine's recommendations for minimizing financial ties and AHRQ's National Guideline Clearinghouse, have met with limited success or have been actively undermined. In 2018, the National Guideline Clearinghouse, which required guidelines to disclose their adherence to transparency standards, was defunded, further obscuring the connection between industry funding and biased recommendations.

Context

• The IOM's efforts are part of a broader movement to improve the reliability and credibility of medical guidelines by reducing the impact of commercial interests.
• The Agency for Healthcare Research and Quality (AHRQ) is a U.S. government agency tasked with improving the quality, safety, efficiency, and effectiveness of healthcare for all Americans.
• These standards were designed to ensure that guidelines were developed based on unbiased evidence, free from undue influence by industry or other vested interests.
• The defunding of the NGC in 2018 was primarily due to budget cuts, which led to the discontinuation of its operations.

U.S. Lacks Supervision and Cost-Effectiveness Evaluation of New Drugs and Technologies

This section delves into the inadequacy of U.S. policy in evaluating the actual worth of new medications and medical technologies, leaving doctors and patients exposed to manipulation by commercially driven narratives.

The Food and Drug Administration and AHRQ Cannot Consider Drug Prices or Compare Effectiveness for Coverage Decisions

In contrast to other affluent nations, the U.S. lacks a government agency tasked with assessing if recently developed medications are worth their costs and making price negotiations according to clinical value. The FDA evaluates only how safe and effective a drug is, not its cost-effectiveness. The AHRQ, while supporting medicine based on evidence, cannot consider cost in making recommendations. Although the National Academy of Medicine suggested an independent government program to oversee systematic reviews and guidelines, the Robert Wood Johnson Foundation, the report’s sponsor, explicitly prohibited any cost-effectiveness considerations. Worse yet, the author highlights that the 2010 Obamacare legislation explicitly prohibited federal agencies from taking cost-effectiveness into account in their decisions on coverage or recommendations for policy guidelines.

Practical Tips

• Advocate for value-based medication pricing by writing to your representatives. While you might not be able to negotiate drug prices yourself, you can influence those who can. Draft a letter explaining the importance of assessing the value of medications and how it can benefit not just you but the community at large. Encourage policymakers to consider establishing mechanisms for evaluating and negotiating drug prices.
• You can evaluate the impact of healthcare decisions on your personal budget by creating a simple cost-effectiveness chart. Start by listing the healthcare services you use or consider using, then research and note their costs and effectiveness based on available data. This will help you make informed decisions about which services provide the best value for your money.
• Start a discussion group with friends or family where you explore the impact of non-financial decisions in your lives. Each member could share a recent decision they made that wasn't based on cost-effectiveness, discussing the outcomes and values that influenced their choice. This practice encourages a community-oriented mindset where decisions are shared and reflected upon beyond monetary terms.
• Create a personal health savings strategy to prepare for potential uncovered expenses. Understanding that cost-effectiveness isn't a federal consideration, you might want to set aside funds specifically for health-related expenses that may not be covered by your insurance. This could involve starting a health savings account (HSA) or a flexible spending account (FSA) to ensure you can afford treatments you deem necessary, even if they are not deemed cost-effective by your insurance provider.

Relying on Biased Information for Treatment Choice

This lack of oversight puts U.S. healthcare providers and recipients at a significant disadvantage. With limited access to unbiased information about how the clinical value and economic efficiency of new drugs measure up against existing therapies, American physicians are susceptible to making prescribing decisions based largely on commercially curated information, ultimately leading to higher costs and potentially less effective care.

Context

• Pharmaceutical companies often sponsor CME programs, which can introduce bias into the educational content that healthcare providers rely on for staying informed about new treatments.
• Patients may receive treatments that are not the most effective or appropriate for their condition, leading to suboptimal health outcomes and increased healthcare costs.
• Financial relationships between healthcare providers and pharmaceutical companies can create conflicts of interest, where prescribing decisions may be influenced by personal gain rather than patient benefit.